1. Büller HR, Agnelli G, Hull RD, Hyers TM, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S–428S.
2. van en Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000;CD001100.
3. Simmonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l´embolie pulmonaire. N Engl J Med 1997;337:663–9.
4. Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004;140:867–73.
5. Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;348:1695–702.
6. Arcasoy SM, Vachani A. Local and systemic thrombolytic therapy for acute venous thromboembolism. Clin Chest Med 2003;24:73–91.
7. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. Circulation 2004;110:744–9.
8. Konstantinides S, Geibel A, Heusel G, Heinrich F, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143–50.
9. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263–8.
10. Kucher N, Printzen G, Doernhoefer T, Windecker S, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576–8.
11. Forster A, Wells P. Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: a systematic review. Chest 2001;119:572–9.
12. Reekers JA, Baarslag HJ, Koolen MG, Van Delden O, et al. Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol 2003;26:246–50.
13. Baldwin ZK, Comerota AJ, Schwartz LB. Catheter-directed thrombolysis for deep venous thrombosis. Vasc Endovascular Surg 2004;38:1–9.
14. Augustinos P, Ouriel K. Invasive approaches to treatment of venous thromboembolism. Circulation 2004;110:127–34.
15. Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:3669–77.
16. Decousus A, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409–15.
17. Gulba DC, Schmid C, Borst HG, Lichtlen P, et al. Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994;343:576–7.
18. Kniemeyer HW, Sandmann W, Schwindt C, Grabitz K, et al. Thrombectomy with arteriovenous fistula for embolizing deep venous thrombosis: an alternative therapy for prevention of recurrent pulmonary embolism. Clin Investig 1993;72:40–5.
19. Schellong SM, Schwarz T, Kropp J, Prescher Y, et al. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost 1999;82:127–9.
20. Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost 2001;85:42–6.
21. Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000;32:861–9.
22. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682–7.
23. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677–81.
24. Schwarz T, Schmidt B, Höhlein U, Beyer J, et al. Eligibility for home treatment of deep vein thrombosis: prospective study. Br Med J 2001;322:1212–3.
25. Beer JH, Burger M, Gretener S, Bernard-Bagattini S, et al. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 2003;1:186–7.
26. Penede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001;103:2453–60.
27. Levine MN, Raskob G, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant treatment. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:287S–310S.
28. Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457–60.
29. Prandoni P, Lensing AW, Bagatella P, Simioni P, et al. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism (letter). Thromb Haemost 1999;82:158–9.
30. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661–5.
31. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med 1998;104:332–8.
32. Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:117–21.
33. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393–8.
34. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901–7.
35. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–34.
36. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631–9.
37. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2002;1:1906–13.
38. Pineo GF, Hull RD. Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother 2003;4:2355–62.
39. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.
40. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res 2002;108:3–13.
41. Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 2005;4:405–13.
42. Brandjes DPM, Büller HR, Heijboer H, et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759–62.
43. Prandoni P, Lensing AWA, Prins MH, Frulla M, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome. A randomized controlled trial. Ann Intern Med 2004;141:249–56.
44. Philbrick JT, Becker DM. Calf deep vein thrombosis. Arch Intern Med 1988;148:2131–8.
45. Schwarz T, Thomas Z, Schellong S. Therapy of isolated calf muscle vein thrombosis with low-molecular-weight-heparin: Prospective randomized study. JTH 2005;3(Suppl 1):Abstract Number OR146.
46. Blumenberg RM, Barton E, Gelfand ML, Skudder P, et al. Occult deep vein thrombosis complicating superficial thrombophlebitis. J Vasc Surg 1998;27:338–43.
47. Enoxaparin SG. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a non-steroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003;163:1657–63.
48. Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulm Med 1999;5:222–6.
49. Warkentin TE, Greinacher A (eds.). Heparin-induced Thrombocytopenia. 3rd edition. New York, Basel: Marcel Dekker, 2004.
Sandra Hochauf, Prof. Dr. Sebastian M. Schellong, Universitätsklinik Dresden „Carl Gustav Carus“, Medizinische Klinik III, Arbeitsbereich Angiologie, Fetscherstraße 74, 01307 Dresden, E-Mail: firstname.lastname@example.org